title: Plasminogen activator inhibitor-1 promoter polymorphism is not associated with the aggressiveness of disease in prostate cancer.
abstract: OBJECTIVE
  PAI-1 (plasminogen activator inhibitors-1) regulates plasminogen activation, and is related to tumour development. This study aims to test whether the promoter polymorphism in the PAI-1 gene is related to the aggressiveness of disease in prostate cancer.
  
  
  METHODS
  In the present study, Taqman SNP genotyping assay was used to detect PAI-1 4G/5G polymorphism in DNA from paraffin-embedded tissues of 98 Caucasian patients with prostate cancer.
  
  
  RESULTS
  The distribution of the genotypes is in Hardy-Weinberg equilibrium. The genotype had no statistically significant relationship with other prognostic factors. Similar risks for recurrence were seen in individuals with the 4G/4G and 4G/5G genotypes compared to those with 5G/5G genotype (odds ratio [OR] 2.65, 95% CI: 0.41-16.94, P = 0.30; OR = 2.19, 95% CI: 0.38-12.49, P = 0.38).
  
  
  CONCLUSIONS
  We concluded that PAI-1 promoter polymorphism is not associated with the aggressiveness of disease in prostate cancer.
authors.affiliation: Department of Thoracic Surgery, Cancer Hospital/Cancer Institute, Fudan University, Shanghai, People's Republic of China.
authors.forename: H
authors.initials: H
authors.lastname: Li
authors.forename: E T
authors.initials: ET
authors.lastname: Shinohara
authors.forename: Q
authors.initials: Q
authors.lastname: Cai
authors.forename: H
authors.initials: H
authors.lastname: Chen
authors.forename: R
authors.initials: R
authors.lastname: Courtney
authors.forename: C
authors.initials: C
authors.lastname: Cao
authors.forename: Z
authors.initials: Z
authors.lastname: Wang
authors.forename: M
authors.initials: M
authors.lastname: Teng
authors.forename: W
authors.initials: W
authors.lastname: Zheng
authors.forename: B
authors.initials: B
authors.lastname: Lu
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000235:genetics*; D017395:Plasminogen Activator Inhibitor 1 / Q000235:genetics*; D011110:Polymorphism, Genetic; D011379:Prognosis; D011401:Promoter Regions, Genetic / Q000235:genetics*; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology; D018570:Risk Assessment; D012307:Risk Factors
chemical_list: D017395:Plasminogen Activator Inhibitor 1